At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 281 enrolled
Drug / intervention
Olpasiran +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Olpasiran (AMG 890) in Subjects With Elevated Lipoprotein(a)
In Brief
A Phase 2 clinical trial evaluating Olpasiran and Placebo for Cardiovascular Disease. Completed, enrolled 281 participants across 36 sites in 7 countries.
Detailed Summary
Evaluate the effect of olpasiran administered subcutaneously (SC) compared with placebo, on percent change from baseline in lipoprotein(a) (Lp\[a\]).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiovascular Disease
CountriesAustralia, Canada, Denmark, Iceland, Japan, Netherlands, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedFeb 2020
Enrollment StartJul 2020
Primary CompletionDec 2021
Study CompletionNov 2022
TodayJul 2026
First PostedFeb 17, 2020
Enrollment StartJul 28, 2020
Primary CompletionDec 27, 2021
Study CompletionNov 8, 2022
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 6.4 years ago
Interventions
Olpasirandrug
Dose 1 Dose 2 Dose 3 Dose 4
Placebodrug
Dose 5